Inhibitory effects of beraprost on platelet aggregation: Comparative study utilizing two methods of aggregometry

Thrombosis Research

Volumn 94, Issue 1, 1999, Pages 25-32

  Yang, Libo ^a   Yatomi, Yutaka ^a   Satoh, Kaneo ^a   Ozaki, Yukio ^a  

^a UNIVERSITY OF YAMANASHI   (Japan)

Author keywords

Beraprost; cAMP; Light scattering; Light transmission; Platelet aggregation; Prostacyclin

Indexed keywords

15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; BERAPROST; THROMBOXANE A2 DERIVATIVE;

ARTICLE; DRUG EFFECT; HUMAN; HUMAN CELL; PRIORITY JOURNAL; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOSIS;

15-HYDROXY-11 ALPHA,9 ALPHA-(EPOXYMETHANO)PROSTA-5,13-DIENOIC ACID; ADENOSINE DIPHOSPHATE; BINDING SITES; BLOOD PLATELETS; CHOLESTEROL; COLLAGEN; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; EPINEPHRINE; EPOPROSTENOL; HUMANS; IODINE RADIOISOTOPES; LIPOPROTEINS, HDL; METHODS; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET COUNT; PROTEIN KINASE C; SCATTERING, RADIATION; VASOCONSTRICTOR AGENTS;

EID: 0033119095     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0049-3848(98)00187-X     Document Type: Article

References (30)

1. Motwani J.G., Topol E.J. Aortocoronary saphenous vein graft disease. Pathogenesis, predisposition, and prevention Circulation. 97:1998;916-931.
2. Goldszmidt A., Wityk R.J. Recent advances in stroke therapy. Curr Opin Neurol. 11:1998;57-64.
3. Joseph J.E., Machin S.J. New antiplatelet drugs. Blood Rev. 11:1997;178-190.
4. Theroux P. Antiplatelet therapy. Do the new platelet inhibitors add significantly to the clinical benefits of aspirin? Am Heart J. 134:1997;S62-S70.
5. Miller D.B. Secondary prevention for ischemic heart disease. Relative numbers needed to treat with different therapies. Arch Intern Med. 157:1997;2045-2052.
6. Born G.V.R. Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature. 194:1962;927-929.
7. Born G.V.R. Observations on the change in shape of blood platelets brought about by adenosine diphosphate. J Physiol. 209:1970;487-511.
8. Nichols A.R., Bosmann H.B. Platelet aggregation. Newly quantified using non-empirical parameters Thromb Haemost. 42:1979;679-693.
9. Kitek A., Breddin K. Optical density variations and microscopic observations in the evaluation of platelet shape change and microaggregate formation. Thromb Haemost. 44:1980;154-158.
10. Gear A.R., Lambrecht J.K. Reduction in single platelets during primary and secondary aggregation. Thromb Haemost. 45:1981;298.
11. Ozaki Y., Satoh K., Yatomi Y., Yamamoto T., Shirasawa Y., Kume S. Detection of platelet aggregates with a particle counting method using light scattering. Anal Biochem. 218:1994;284-294.
12. Yamamoto T., Egawa Y., Shirasawa Y., Ozaki Y., Sato K., Yatomi Y., Kume S. A laser light scattering in situ system for counting aggregates in blood platelet aggregation. Meas Sci Technol. 6:1995;174-180.
13. Fukuda K., Ozaki Y., Satoh K., Kume S., Tawata M., Onaya T., Sakurada K., Seto M., Sasaki Y. Phosphorylation of myosin light chain in resting platelets from NIDDM patients is enhanced. Correlation with spontaneous aggregation Diabetes. 46:1997;488-493.
14. Iwase E, Tawata M, Aida K, Ozaki Y, Kume S, Satoh K, Qi R, Onaya T. A cross-sectional evaluation of spontaneous platelet aggregation in relation to complications in patients with type II diabetes mellitus. 1998;47:699-705.
15. Tohgi H., Takahashi H., Watanabe K., Kuki H., Shirasawa Y. Development of large platelet aggregates from small aggregates as determined by laser-light scattering. Effects of aggregant concentration and antiplatelet medication Thromb Haemost. 75:1996;838-843.
16. Qi R., Ozaki Y., Satoh K., Yang L., Asazuma N., Yatomi Y., Kume S. Intracellular levels of cAMP and cGMP differentially modify platelet aggregate size in platelets activated with epinephrine or ADP. J Cardiovasc Pharmacol. 28:1996;215-222.
17. Qi R., Ozaki Y., Satoh K., Kurota K., Asazuma N., Yatomi Y., Kume S. Quantitative measurement of various 5-HT receptor antagonists on platelet activation induced by serotonin. Thromb Res. 81:1996;43-54.
18. Satoh K., Ozaki Y., Qi R., Yang L., Asazuma N., Yatomi Y., Kume S. Factors that affect the size of platelet aggregates in epinephrine-induced activation. A study using the particle counting method based upon light scattering Thromb Res. 81:1996;515-523.
19. Moncada S., Gryglewski R., Bunting S., Vane J.R. An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature. 263:1976;663-665.
20. Marcus A.J., Weksler B.B., Jaffe E.A., Broekman M.J. Synthesis of prostacyclin from platelet-derived endoperoxides by cultured human endothelial cells. J Clin Invest. 66:1980;979-986.
21. Murata T., Ushikubi F., Matsuoka T., Hirata M., Yamasaki A., Sugimoto Y., Ichikawa A., Aze Y., Tanaka T., Yoshida N., Ueno A., Ohishi S., Narumiya S. Altered pain perception and inflammatory response in mice lacking prostacyclin receptor. Nature. 388:1997;678-682.
22. Andersen N.H., Eggerman T.L., Harker L.A., Wilson C.H., De B. On the multiplicity of platelet prostaglandin receptors. I. Evaluation of competitive antagonism by aggregometry. Prostaglandins. 19:1980;711-735.
23. Okuda Y., Sone H., Mizutani S., Asano M., Tsurushima Y., Ogawa M., Tada K., Asakura Y., Kawakami Y., Suzuki S., Yamashita K. Acute effect of beraprost sodium on lower limb circulation in patients with non-insulin-dependent diabetes mellitus-evaluation by color Doppler ultrasonography and laser cutaneous blood flowmetry. Prostaglandins. 52:1996;375-384.
24. 2 analogue, on platelet aggregation in diabetes mellitus. Int J Clin Pharmacol Res. 16:1996;99-102.
25. Saito T., Saitoh S., Asakura T., Kanke M., Owada K., Maruyama Y. Prostacyclin analogue, beraprost, sustains recanalization duration after thrombolytic therapy in acute myocardial infarction model. Int J Cardiol. 38:1993;225-233.
26. Nishio S., Matsuura H., Kanai N., Fukatsu Y., Hirano T., Nishikawa N., Kameoka K., Umetsu T. The in vitro and ex vivo antiplatelet effect of TRK-100, a stable prostacyclin analog, in several species. Jpn J Pharmacol. 47:1988;1-10.
27. Sim A.K., McCraw A.P., Cleland M.E., Nishio S., Umetsu T. Effect of a stable prostacyclin analogue on platelet function and experimentally-induced thrombosis in the microcirculation. Arzneimittel-Forschung. 35:1985;1816-1818.
28. Siess W. Molecular mechanisms of platelet activation. Physiol Rev. 69:1989;58-178.
29. Thompson N.T., Scrutton M.C., Wallis R.B. Particle volume changes associated with light transmittance changes in the platelet aggregometer. Dependence upon aggregating agent and effectiveness of stimulus Thromb Res. 41:1986;615-626.
30. Rhee S.G., Bae Y.S. Regulation of phosphoinositide-specific phospholipase C isozymes. J Biol Chem. 272:1997;15045-15048.